Down, Not Out: Neuralstem's NSI-566 Phase 2 Data And Potential

While this author is not in complete agreement with Mr. Feuerstein, the author acknowledges several fair points that investors should objectively consider. Neuralstem is a dual platform regenerative medicine company.

http://ift.tt/1BRikiw